dual AAV vectors
AAV platform
commercialization
project plans
forms of retinitis pigmentosa
concept project spins
RetGeneTx ERC project
innovative gene therapy platform
AAV DNA transfer capacity
GeneVision proof
USHIB
retinal application
data
early phase clinical development
non-retinal diseases
Usher syndrome type Ib
initial proof
development of therapies
seed funding
business plan
large genes
longer plan
delivery of genes
early onset
pivotal trial
consolidator ERC grant
additional rounds of funding
inherited blinding conditions
European Medicina Agency
major discovery
Stargardt disease
patent applications
principle investigator
Orphan Drug Designation
size
proposal
animal models
mutations
best
start-up company
market authorization
foundations
cure
GeneVisionâ€™s objective
single AAVs
activities
success